title: Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
abstract: An 11-year-old male was diagnosed with chronic-phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon-α2b and low-dose cytarabine. In 6 years, he progressed to lymphoid blast crisis and received induction chemotherapy with prednisolone, vincristine, daunorubicin, and l-asparaginase concomitantly with imatinib 400 mg/day, and continuation with vincristine + prednisolone, cytarabine + etoposide, vincristine + l-asparaginase, cyclophosphamide + etoposide, and 6-mercaptopurine + methotrexate. Complete molecular response (MR) was achieved and therapy was continued with imatinib 800 mg/day. He relapsed to chronic-phase CML after interruption of imatinib and regained MR after its restart. The patient is alive 17.5 years after CML diagnosis and 11.5 years after lymphoid blast crisis.
authors.affiliation: Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia. amaschan@mail.ru.
authors.forename: Alexey
authors.initials: A
authors.lastname: Maschan
authors.affiliation: Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia.
authors.forename: Galina
authors.initials: G
authors.lastname: Novichkova
authors.affiliation: Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia.
authors.forename: Natalia
authors.initials: N
authors.lastname: Miakova
authors.affiliation: Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation, Moscow, Russia.
authors.forename: Marina
authors.initials: M
authors.lastname: Persiantseva
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000188:drug therapy*; D002648:Child; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate
keywords: CML; chemotherapy; imatinib; lymphoid blast crisis